• Yi Pan, Rui Chang, Zhonglin He, and Ming Hong.
• The Ninth People's Hospital of Chongqing.
• Medicine (Baltimore). 2021 Apr 9; 100 (14): e25360e25360.

IntroductionHepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and most patients in China are diagnosed at the intermediate or later stages, which is not suitable for the first line therapies. Transarterial chemoembolization (TACE) is a commonly selected therapeutic option for intermediate and later stage HCC in China, but patients often suffer from postembolization syndrome (PES), manifesting as fever, liver area pain, nausea, vomiting, paralyzed intestinal obstruction, and abdominal pain after TACE. We try to conduct a double blinded, randomized, placebo-controlled clinical trial to observe whether Chaihu Guizhi decoction (CGD), a classic traditional Chinese formula, could prophylactically alleviate the incidence of PES in HCC patients after TACE.MethodsPatients will be randomly assigned sequentially in a 1:1 ratio by using preformed randomization envelopes. After TACE procedures, patients in the treatment group will be administrated with Chinese herbal formula CGD, and patients in the control group with CGD simulations, twice a day, continuously for 7 days. The outcomes are the incidence of PES hospitalization and, complications. SPSS version 22 (IBM, Chicago, IL) will be used for the data, and a P < .05 will be considered statistically significant.ConclusionsThe findings will explore the prophylactic effect of CGD in alleviating the incidence of PES following TACE in HCC patients.Trial RegistrationOSF Registration number: DOI 10.17605/OSF.IO/FKRSN.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

51 keywords...

hide…